Company: NCEL
Filing Date: 2025-09-04
Form Type: 425
Source: 0001213900-25-084283
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-09-04
Form: 425
Chunk 1
---
='center'>NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients</div>

| - | Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United States and India |

| - | Hong Kong represents a meaningful diabetes market and a critical gateway into Mainland China—including the Greater Bay Area—supporting 
 future clinical collaboration, partnering and commercialization paths for IsletRx.                                                     |

Zurich, Switzerland — September 4, 2025
— NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (“NLS” or the “Company”) today announced that its merger
partner Kadimastem Ltd. (TASE: KDST) (“Kadimastem”) has been granted a patent by the Hong Kong Intellectual Property
Department covering Kadimastem’s proprietary cell selection and enrichment technology used in the development of IsletRx, a stem
cell–derived therapy candidate intended to treat—and potentially cure—insulin-dependent diabetes.

According to Kadimastem, the Hong Kong patent
adds to previously granted patents in Europe, the United States and India, further strengthening the global protection around IsletRx.
The patented process enables the selection and enrichment of highly functional islet cells from differentiated cell populations to help
maximize therapeutic effect.

Alexander Zwyer, Chief Executive Officer of NLS Pharmaceutics,
commented:

“We congratulate Kadimastem on this important intellectual property
(IP) milestone. Expanding protection into Hong Kong—a key life-sciences hub in Asia—supports the long-term strategy for IsletRx
and Kadimastem’s broader diabetes program. With hundreds of millions of people worldwide living with diabetes, continued progress
on strong, defensible intellectual property is essential as Kadimastem works toward clinical development and future patient access.”

Ronen Twito, Executive Chairman and CEO of Kadimastem, commented:

“This additional patent approval in Hong Kong is an important
milestone in strengthening our global IP portfolio for IsletRx. We believe that each new territory where IP protection is secured further
validates the uniqueness of our technology and provides important protection as we advance toward clinical development. Diabetes is a
global challenge, and this patent reinforces our long-term strategy to bring a potentially curative cell therapy to patients worldwide.”

Diabetes represents a significant and growing health and economic
burden in Hong Kong. The